Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds

Platinum Chemo No Better than Standard in BRCA-mutated Early BC, Trial Finds
Women with newly diagnosed breast cancer who carry a mutation in their BRCA genes may continue to receive the standard pre-surgery chemotherapy regimen used for other breast cancer patients, according to findings from a Phase 2 trial. That trial, called INFORM, found that platinum chemotherapy was no more effective than current approaches in treating women with early-stage breast cancer carrying BRCA mutations. The findings of the study, “TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial),” were published in the Journal of Clinical Oncology. Platinum-based chemotherapy is known to have promising activity in BRCA-mutated breast cancers. The INFORM trial (NCT01670500) investigated whether the platinum chemotherapy agent cisplatin was better than standard chemo in women with early-stage breast cancer carrying BRCA mutations. The results showed that platinum chemo was no more effective than current approaches using doxorubicin and cyclophosphamide. "Previous studies reported that the platinum-based therapy cis
Subscribe or to access all post and page content.